NEW YORK (GenomeWeb) – Data analytics firm CollabRx has inked a non-exclusive deal with Quest Diagnostics to provide the company with its medical annotation services.
Under the agreement, Quest will have access to medical content services from CollabRx, such as scientific literature, medical guidelines, and published therapeutic protocols. The services, marketed as Genetic Variant Annotation, were developed by CollabRx but customized by Quest.
Doctors that use Quest's next-generation sequencing services to perform genetic analysis on cancer patients will have access to this medical content to help them guide treatment strategies. “The annotated content may help physicians better understand, through the database, the clinical significance of test results indicating the presence of one or more gene mutations,” CollabRx said in a statement, highlighting that Quest each year serves approximately half the physicians and hospitals in the US.
As part of the deal, Quest can also use CollabRx content to inform clinical trials that it is performing with drug developers and other partners.
The firms did not disclose additional details of their agreement.